PubMed
PubMed® comprises more than 35 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher websites. PubMed is a free resource supporting the search and retrieval of biomedical and life sciences literature with the aim of improving health–both globally and personally. The PubMed database contains more than 35 million citations and abstracts of biomedical literature. It does not include full text journal articles; however, links to the full text are often present when available from other sources, such as the publisher's website or PubMed Central (PMC). Citations in PubMed primarily stem from the biomedicine and health fields, and related disciplines such as life sciences, behavioral sciences, chemical sciences, and bioengineering. MEDLINE is the largest component of PubMed and consists primarily of citations from journals selected for MEDLINE.
Learn more
Compier Literature Screening
Compier Literature Screening is an AI-driven platform designed to assist pharmacovigilance professionals in efficiently screening abstracts, full texts, and translated articles to identify patients, authors, events, products, and safety-related information. The platform offers built-in integration with online biomedical databases such as Medline and supports bulk uploading of literature records from sources like Embase, conference presentations, and PDF journals. It performs automated duplicate checks for each literature search and utilizes validated AI models for automatic screening and annotation of entities. Users can configure scalable literature screening workflows tailored to specific requirements and global regulations. The system facilitates communication with third-party vendors to obtain full texts and includes built-in translation capabilities. It also integrates with safety systems, such as Oracle Argus Safety, to transmit ICSR-relevant articles.
Learn more
BenevolentAI
BenevolentAI is an AI-enabled drug discovery platform and scientific technology company that unites advanced artificial intelligence, machine learning, and domain-specific science to accelerate the discovery, design, and development of new medicines for complex diseases by making sense of vast, diverse biomedical data and generating actionable scientific insights faster than traditional methods. Its proprietary Benevolent Platform ingests and harmonizes structured and unstructured biomedical information, including literature, genomics, clinical information, and multi-omics data, into a comprehensive knowledge graph, enabling scientists to reason across biological systems, generate hypotheses, predict novel drug targets, and design candidate molecules with higher confidence and lower failure rates.
Learn more
Ovid
Every day, nurses, doctors, students, professors, healthcare administrators, and allied health professionals rely on Ovid to provide the most up-to-date research, including resources from 120+ publishers, covering over 100 specialty areas. Dedicated to bringing the best research and key information to clinical practice, the New England Journal of Medicine (NEJM) is known as a career companion for physicians, keeping practicing physicians informed on developments that are important to their patients. The highly rigorous peer-review and editing process to evaluate manuscripts ensures scientific accuracy, novelty, and importance. NEJM on Ovid® offers landmark research, clinical insights, and medical breakthroughs in over 125 areas all accessible through the world’s most trusted medical research platform. Ovid® Synthesis Clinical Evidence Manager is an easy-to-use, cloud-based application with unparalleled literature search and review capabilities.
Learn more
